| - |
Dronedarone |
Multaq® |
__ |
Rapid review complete |
12th January 2010 |
 |
| 22073 |
Drospirenone/estetrol monohydrate |
Drovelis® |
Drospirenone/estetrol monohydrate is indicated for oral contraception. |
Rapid Review Complete |
6th July 2023 |
|
| - |
Dulaglutide |
Trulicity® |
As monotherapy for the treatment of adult patients with T2DM when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications. Dulaglutide is indicated as an add-on therapy in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. |
Rapid review complete |
29th April 2015 |
|
| 23047 |
Dupilumab |
Dupixent® |
Dupilumab (Dupixent®) is indicated for the treatment of adults and adolescents 12 years and older, weighing at least 40 kg, with eosinophilic oesophagitis (EoE) who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy. |
Rapid Review Complete |
7th September 2023 |
|
| 19056 |
Dupilumab |
Dupixent® |
For the treatment of moderate-to-severe atopic dermatitis in adolescents 12 years and older who are candidates for systemic therapy. |
Rapid review complete |
17th January 2020 |
|
| 23043 |
Dupilumab |
Dupixent® |
Dupilumab (Dupixent®) is indicated for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. |
Rapid Review Complete |
24th August 2023 |
|
| 23044 |
Dupilumab |
Dupixent® |
Dupilumab (Dupixent®) is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment. |
Rapid Review Complete |
5th September 2023 |
|
| 21063 |
Dupilumab |
Dupixent® |
For adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance. |
Rapid review complete |
14th March 2024 |
|
| 21035 |
Dupilumab |
Dupixent® |
For severe atopic dermatitis in children 6 to 11 years old who are candidates for systemic therapy. |
Rapid review complete |
23rd September 2021 |
|
| 23042 |
Dupilumab |
Dupixent® |
Dupilumab is indicated for the treatment of severe atopic dermatitis in children aged 6 months to 6 years old who are candidates for systemic therapy. |
Rapid Review Complete |
1st September 2023 |
|
| 23046 |
Dupilumab |
Dupixent® |
Dupilumab (Dupixent®) is indicated as an add-on therapy with intranasal corticosteroids, for the treatment of adults with severe chronic rhinosinusitis with nasal polyposis for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control. |
Awaiting full HTA submission from Applicant |
28th September 2023 |
|
| - |
Dupilumab |
Dupixent® |
For treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy. |
NCPE Assessment Process Complete |
12th December 2019 |
|
| 24035 |
Dupilumab |
Dupixent® |
Dupilumab is indicated in adults as an add-on maintenance treatment for uncontrolled COPD characterised by raised blood eosinophils on a combination of an ICS, a LABA, and a LAMA, or on a combination of a LABA and a LAMA, if an ICS is not appropriate. |
Awaiting full HTA submission from Applicant |
10th October 2024 |
|
| - |
Durvalumab |
Imfinzi® |
For the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 ≥1% on tumour cells and whose disease has not progressed following platinum-based chemo-radiation therapy (CRT). |
NCPE Assessment Process Complete |
7th May 2020 |
|
| 21033 |
Durvalumab |
Imfinzi® |
In combination with etoposide and either carboplatin or cisplatin, for the first-line treatment of adult patients with extensive-stage small cell lung cancer. |
Rapid review complete |
9th September 2021 |
|
| 23009 |
Durvalumab |
Imfinzi® |
Durvalumab in combination with gemcitabine and cisplatin is indicated for the first-line treatment of adults with unresectable or metastatic biliary tract cancer. |
NCPE Assessment Process complete |
19th December 2024 |
|
| 24036 |
Dispersible tablet (DT) (dolutegravir sodium, abacavir sulphate, and lamivudine). HTA ID: 24036 |
Triumeq® |
Triumeq® DT is indicated for Human Immunodeficiency Virus type 1 (HIV-1) infection in children of at least three months of age and weighing at least 6 kg to less than 25 kg |
Rapid Review Complete |
18th October 2024 |
|
